IMMUNEERING RAISES $20 MILLION FOR NEW DRUG-DISCOVERY EFFORT
Company formed in 2008 also provides services to pharmaceutical companies
By Brian Gormley
Venture capitalists are betting $20 million that technology from Immuneering Corp. will enable it to develop medicines aimed at molecular targets that have long tantalized and eluded drugmakers.
